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Abstract
Background: Most tumor cells show aberrantly activated Akt which leads to increased cell survival and resistance
to cancer radiotherapy. Therefore, targeting Akt can be a promising strategy for radiosensitization. Here, we explore
the impact of the Akt inhibitor MK-2206 alone and in combination with the dual PI3K and mTOR inhibitor PI-103 on
the radiation sensitivity of glioblastoma cells. In addition, we examine migration of drug-treated cells.
Methods: Using single-cell tracking and wound healing migration tests, colony-forming assay, Western blotting,
flow cytometry and electrorotation we examined the effects of MK-2206 and PI-103 and/or irradiation on the
migration, radiation sensitivity, expression of several marker proteins, DNA damage, cell cycle progression and the
plasma membrane properties in two glioblastoma (DK-MG and SNB19) cell lines, previously shown to differ
markedly in their migratory behavior and response to PI3K/mTOR inhibition.
Results: We found that MK-2206 strongly reduces the migration of DK-MG but only moderately reduces the migration
of SNB19 cells. Surprisingly, MK-2206 did not cause radiosensitization, but even increased colony-forming ability after
irradiation. Moreover, MK-2206 did not enhance the radiosensitizing effect of PI-103. The results appear to contradict
the strong depletion of p-Akt in MK-2206-treated cells. Possible reasons for the radioresistance of MK-2206-treated cells
could be unaltered or in case of SNB19 cells even increased levels of p-mTOR and p-S6, as compared to the reduced
expression of these proteins in PI-103-treated samples. We also found that MK-2206 did not enhance IR-induced DNA
damage, neither did it cause cell cycle distortion, nor apoptosis nor excessive autophagy.
Conclusions: Our study provides proof that MK-2206 can effectively inhibit the expression of Akt in two glioblastoma
cell lines. However, due to an aberrant activation of mTOR in response to Akt inhibition in PTEN mutated cells, the
therapeutic window needs to be carefully defined, or a combination of Akt and mTOR inhibitors should be considered.
Keywords: DNA damage, Glioblastoma Multiforme, Histone H2AX, Irradiation, Migration, mTOR, PTEN, p53, Radiation
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Background
The frequent activation of the PI3K pathway in cancer
cells and its crucial role in cell growth and survival has
made it a promising target for pharmacologic intervention
(for review, see [1]). Especially Akt, the most crucial pro-
ximal node downstream of the RTK (receptor tyrosin-
kinase)-PI3K complex, is commonly over-expressed or
-activated in all major cancers [2]. Through a number of
downstream effectors, such as mTOR, p-4E-BP1 and
p-S6K, Akt plays a key role in tumor cell survival and pro-
liferation. Genetic alterations leading to activation of the
PI3K/Akt/mTOR pathway are associated with treatment
resistance in a variety of solid tumors [3]. Patients whose
tumors expressed high levels of p-Akt had decreased
survival outcomes and increased metastatic spread after
standard chemoradiation [4]. For these reasons, Akt is
considered a promising target for cancer therapy and
inhibition of Akt alone or in combination with standard
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cancer chemotherapeutics has been postulated to
reduce the apoptotic threshold and preferentially kill
cancer cells [2].
The development of Akt inhibitors has been complicated
and hampered by the presence of three Akt isozymes
(Akt1, Akt2 and Akt3) which differ in function and tissue
distribution [5]. Several classes of Akt inhibitors have been
developed, including (i) lipid-based phosphatidyl-inositol
analogues, (ii) ATP-competitive inhibitors, and (iii) allo-
steric inhibitors. One member of the allosteric class is
MK-2206, an oral, highly selective inhibitor of Akt1, Akt2
and Akt3. MK-2206 binds to the pleckstrin-homology
domain of Akt, causing a conformational change that
prevents the localization of Akt to the plasma membrane
and its subsequent activation [6, 7].
In preclinical models, MK-2206 enhanced the activity
of standard chemotherapeutic (carboplatin, gemcitabine,
docetaxel, doxorubicin) and molecularly targeted (erloti-
nib or lapatinib) agents in various lung, breast, ovarian,
gastric or hepatocellular carcinoma cell lines [8, 9].
Moreover, combination of MK-2206 and the MEK1/2
inhibitor AZD6244 resulted, through increased apoptosis,
in synergistic inhibition of A549 and H157 lung cancer
cell growth in vitro and in vivo [10].
Sensitivity to Akt-specific inhibitors is dependent upon
activation of the PI3K/Akt/mTOR pathway in tumor cells
[11]. Interestingly, catalytic Akt inhibitors (e.g. GDC-0068
and AZD5363) have inhibitory effects in breast tumor cell
lines with Akt mutations, whereas allosteric inhibitors (e.g.
MK-2206) do not exert inhibitory effect on breast, colon
and ovarian cancer cells [12, 13]. On the other side,
MK-2206, AZD5363 and GDC-0068 have all shown
increased activity in cell lines with PIK3CA or PTEN
alterations [14, 15]. This suggests that Akt inhibitors could
be indicated for tumors with either PTEN loss or PIK3CA
mutation (for review, see [1]). Moreover, MK-2206 alone
more potently inhibited cell growth in Ras wild-type cell
lines as compared to Ras-mutant NSCLC cell lines [8].
Besides promoting tumor cell proliferation and survival,
the Akt/mTOR pathway is recognized as a major pathway
regulating autophagy [16], and inhibitors of the Akt/
mTOR axis, such as rapamycin analogues, can intensify
the autophagic process [17]. Thus, the Akt inhibitor 1
L-6-hydroxymethyl1-chiro-inositol 2(R)-2-O-methyl-3-O-
octadecylcarbonate induces authophagic, but not apop-
totic cell death, in both radioresistant (U87-MGΔEGFR)
and radiosensitive U87-MG glioma cell lines and it
enhances sensitivity to radiation [18]. MK-2206 also
induces autophagy, as demonstrated by an increase in the
14-kDa form of LC3A/B in hepatocarcinoma cells [9].
In addition to in vitro studies, early-phase clinical
trials with allosteric (MK-2206) and catalytic (GDC-0068)
Akt inhibitors support the hypothesis that Akt inhibi-
tors can be effective in tumors with PTEN deficiency
[1]. Tumor shrinkage has been reported in PTEN-de-
ficient pancreatic cancer cells of patients who received
MK-2206 [19].
Beside cytostatic effects, MK-2206 used either alone [20,
21] or in combination with e.g. rapamycin [22] increases
radiation sensitivity of various tumor cell lines. Li et al.
(2009) showed that Akt inhibition with MK-2206 in-
creased radiation sensitivity of U87-MG cells [20]. Chau-
tard et al. (2010), using a clonogenic survival assay, which
was recommended to be named as “percent clone forming
test” [23], demonstrated a significant enhancement of
radiation sensitivity by an Akt inhibitor IV in human
malignant glioma cells [21]. Molecular targeting of Akt by
MK-2206 also led to a radiosensitization of lung car-
cinoma cells which did not respond to the rapamycin
(mTORC1 inhibitor) treatment [22]. Moreover, compared
to Akt inhibition alone, the dual targeting of Akt1 and
mTORC1 markedly enhanced the frequency of residual
DNA double-strand breaks (DSBs) by inhibiting the
non-homologous end joining repair pathway [22].
We have shown previously that prolonged incubation of
several tumor cell lines with the dual PI3K/mTOR-inhibi-
tor PI-103 leads to a re-activation of p-Akt, which in turn
might increase tumor cell growth and survival [24]. Given
the major roles of Akt in regulating tumor cell survival
and resistance to radio- and chemotherapy, we evaluated
in this study whether its inhibitor MK-2206 has potential
as a radiosensitizing and/or anti-migratory agent in glio-
blastoma multiforme (GBM) cells. In addition, we exa-
mined whether MK-2206 can enhance the radiosensitizing
effect of PI-103. We analyzed the impact of MK-2206
alone or in combination with irradiation (IR) and PI-103
on the migration and radiation response of two GBM cell
lines differing in PTEN and p53 mutation status. To this
end, we analyzed control and drug-treated cells by migra-
tion and colony-forming assays, induction and repair of
drug- and radiation-induced DNA damage, and cell-cycle
phase distribution. We also assessed, by Western blotting,
the expression patterns of diverse marker proteins of the
PI3K- and MAPK-pathways (p-Akt, p-mTOR, p-4E-BP1,
p-S6, p-MEK1/2, p-Erk1/2), as well as DNA repair (ATM,
ATR, Rad50 etc.), apoptosis (cleaved PARP, subG1-con-
tent) and autophagy (LC3B, p62) markers. In addition,
plasma membrane properties of control and drug-treated
cells were probed by dielectric spectroscopy.
Methods
Cell culture
DK-MG (#ACC277) and SNB19 (#ACC325, a subclone
of the U-251 MG line according to the provider) human
glioblastoma (GBM) cell lines were purchased (on the
7th March 2006 and 04.09.2001, respectively) from
DSMZ (Braunschweig, Germany) and authenticated by
the supplier. Both GBM cell lines were cultured [24] in
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the respective complete growth medium (CGM) con-
taining 10% fetal bovine serum according to provider’s
prescription. Cells were used at low (< 15) passages
after thawing and were regularly authenticated on the
basis of morphology, growth curve analysis, expression
of PTEN and p53; and were regularly examined during
the study for Mycoplasma (MycoAlert; Lonza, Rockland,
ME, USA).
Inhibitor treatment
Both inhibitors were purchased from Selleckchem
(Absource Diagnostics GmbH, Munich, Germany). The
substances were freshly diluted from frozen (− 80 °C) ali-
quots dissolved in DMSO. MK-2206 (5 μM, [14]) and
PI-103 (2 μM, [24]) were added alone or in combination 3
h (short-term treatment) prior to exposure to ionizing ra-
diation (IR) and remained in CGM up to 24 h (long-term
treatment) after IR. Control cells were treated in parallel
with respective amounts of DMSO.
Antibodies
The primary and secondary antibodies used in this paper
are indicated in the Additional file 1: Supplemental
Materials.
Irradiation treatment
Irradiation of the samples was performed at room
temperature using a 6 MV Siemens linear accelerator
(Siemens, Concord, CA) at a dose rate of 2 Gymin− 1.
After exposure to IR, cells were further cultured in
CGM for the indicated time until processing [24].
Phase-contrast microscopy of living cells
A Nikon BioStation IM-Q (Nikon, Melville, NY), which
includes a cell incubator (37 °C, 5% CO2), a motorized
inverted phase contrast microscope and a high-sensitivity
CCD camera, was used to image live GBM cells over time
[25]. Prior to single-cell tracking experiments, cells
(about 104 in 2 ml medium) were plated into a Petri
dish (diameter 35 mm). Time-lapse images of several
fields (706 × 530 μm) of view were acquired in each
experiment every 10 min over an 18-h period, using a
10x phase contrast objective.
Individual cell tracking and analysis of migration
Individual cell tracking was performed using the Time
Lapse Analyzer (TLA; University of Ulm, Germany) soft-
ware, tailored for a tracking procedure with automatic cell
identification of unstained cells in phase contrast micro-
scopy videos. Image analysis, including pre-processing and
segmentation for the separation of the cells from the back-
ground, and track generation were performed essentially
as described elsewhere [25]. Using the acquired track
information, cell migration speed and directionality of
migration were calculated for each individual cell. Motility
speed was calculated as the total distance (TD) a cell
travelled divided by the total movement time. Migration
directionality was assessed as the net distance (ND), which
is the shortest way from the starting position to the end of
migration path, where 1.0 corresponds to migration in a
straight line, and 0.0 to migration with an identical start
and endpoint (circular or no movement).
Wound healing (scratch) test
Wound closure in the control or drug-treated cell sam-
ples, non-irradiated or with IR treatment, was examined
up to 18 h after scratching as described elsewhere [25].
A wound or scratch was made with a sterile micro-
pipette tip through confluent cell monolayers plated
on a glass dish. Video images were acquired using a
Biostation IM-Q (Nikon, Melville, NY). Wound closure
rates were quantitated with Image J (Wayne Rasband,
National Institutes of Health, Bethesda, MD).
Colony-forming test
To assess the effect of IR, a standard colony-forming
assay was performed as previously described [24]. Con-
trol and drug-treated cells were irradiated with a single
dose (0, 2, 3, 5, 7 or 8 Gy) of irradiation and seeded 24 h
post-IR in Petri dishes for further cultivation. After
about 10–12 days, fixation (methanol/acetic acid) and
staining with a solution of 0.6% w/v crystal violet was
performed [24]. Only colonies containing more than 50
cells were counted. The mean colony-forming data for
each tested cell line were fitted to the linear-quadratic
(LQ) model (Eq. 1):
CFF ¼ exp −αX−βX2  ð1Þ
where CFF is the colony-forming fraction, X is the
irradiation dose, and α and β are the linear and quadratic
terms of the fitting function. Both the LQ and the LQ-L
(linear-quadratic linear) are state-of-the-art methods for
the analysis of colony-forming ability [26]. Usually a very
good agreement between the observed experimental data
and the estimated regression curves is obtained.
DNA damage and cell-cycle measurements detected by
flow cytometry
Control and drug-treated subconfluent cell cultures were
irradiated with a single radiation dose of 8 Gy and ana-
lyzed by flow cytometry 30 min and 24 h post-IR. A
single dose of 8 Gy used in the study is far higher than
the single daily fraction during radiotherapy of cancer
patients, which ranges between 1.8 and 2 Gy resulting in
a total dose of 50–60 Gy after 4–5 weeks. However, in
order to cause detectable cell cycle disturbances and/or
to enable the detection of γH2AX by flow cytometry or
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apoptosis much higher irradiation doses in the range of
5–12 Gy are required in radiobiological experiments (e.g.
[27–29]). In our experiments, single irradiation with the
clinically relevant dose of 2 Gy did not induce any cell
cycle alterations in SNB19 cells detectable by flow cy-
tometry, both 30 min and 24 h after IR, as compared to
non-irradiated controls (Additional file 2: Table S1). In
sharp contrast, 24 h after irradiation with 8 Gy the cells
exhibited a marked G2-arrest. Likewise, irradiation with
8 Gy had a more pronounced effect on the γH2AX con-
tent (both initially induced and residual) detected by
flow cytometry as compared to cells irradiated with 2 Gy
in glioblastoma SNB19 cells (Additional file 2: Table S2).
At indicated times after IR, cells were detached by tryp-
sinization, washed in PBS, fixed and stained for DNA
damage marker histone γH2AX as previously described
[24]. In addition, the samples were stained with propi-
dium iodide (PI, Sigma P-4170, 10 μg ml− 1) in the pres-
ence of ribonuclease A (Sigma R-5250, 25 μg ml− 1) to
avoid RNA staining. Red (PI-DNA) and green (histone
γH2AX) fluorescence was acquired in linear or logarith-
mic mode, respectively, using a flow cytometer FACS-
CantoII (Becton Dickinson, San Jose, CA). The samples
include both floating and trypsinized cells. The output
data were presented as one-dimensional histograms, i.e.
the distributions of PI-DNA or histone γH2AX signals
within cell samples and analyzed using ModFit LT
(Verity Software House, Topsham, ME) and Flowing
Software obtained from P. Terho (Turku Centre for Bio-
technology, Turku, Finland). In addition, the sub-G1
fraction was evaluated to assess the late-stage apoptosis.
Western blotting
The expression of marker proteins was tested using west-
ern blotting as previously described [24]. Cellular lysates
were prepared 30min and 24 h post-IR according to
standard procedures. Forty μg of protein per lane were
separated using 4–12% SDS-polyacrylamide pre-cast gels
(Invitrogen, Karlsruhe, Germany) and transferred to nitro-
cellulose membranes according to the manufacturer’s
prescriptions. The levels of protein expression were quan-
tified using Image J (Wayne Rasband, National Institutes
of Health, Bethesda, MD) and normalized to β-actin in-
tensity. Experiments were repeated at least three times,
unless otherwise noted.
Electrorotation and derivation of membrane parameters
Measurements of the electric field frequency fc1 that
produced the fastest anti-field rotation of cells were car-
ried out in isotonic (300 mOsm) inositol medium with
the contra-rotating fields (CRF) method as described
previously [30]. The theory of electrorotation predicts
the following relationship between the characteristic fre-
quency of anti-field electrorotation fc1, the cell radius a,
the membrane capacitance Cm [μF/cm
2] and conduct-
ance Gm [mS/cm
2] per unit area:
f c1  a ¼
σe
π  Cm þ
ah i  Gm
2π  Cm ð2Þ
where a and < a > are, respectively, individual and
mean cell radii, σe [μS/cm] is the conductivity of sus-
pending medium, which is much lower than the intra-
cellular conductivity (i.e. σe < < σi). The membrane
quantities Cm and Gm can be derived by fitting Eq. 2 to
the (fc1·a) data plotted against σe [30].
From the Cm and cell radius values, the whole-cell
capacitance CC [pF] was also calculated as:
CC ¼ 4π  a2  Cm ð3Þ
Unlike the Cm value, which represents the area-specific
membrane capacitance, the parameter CC accounts for
the total electrically accessible cell membrane, including
both smooth and folded membrane regions.
Statistical analysis
Data are presented as mean ± SE, unless otherwise stated.
Student’s t-test was performed when statistical compari-
sons were made between two sets of data. Difference with
p-values of <0.05 were considered significant.
Results
Effects of Akt-, PI3K-, and mTOR-inhibition on the
migration of GBM cells
We recently reported that the migration activity of SNB19
cells is much less responsive to PI3K/mTOR inhibition
than that of DK-MG cells [25]. In the present study, we
tested whether Akt inhibition can reduce the motility of
SNB19 cells. First, we examined the migration of indivi-
dual DK-MG and SNB19 cells (Fig. 1 and Additional file 3:
Movie S1) by time-lapse video-microscopy [25].
As evident from the motility diagrams shown in Fig. 1a
and Additional file 3: Movie S1, which are statistically sum-
marized in Fig. 1b, treatment with MK-2206 decreased the
migration speed of DK-MG cells by ~ 30% with respect to
controls cells. In contrast, MK-2206 did not affect the
migration activity of SNB19 cells (Fig. 1b). Data on the
effects of PI-103 have been previously reported [25]. The
effects of both inhibitors on the migration of irradiated
cells were similar to their effects on non-irradiated
samples from both cell lines (data not shown).
Additionally to individual cell tracking, we analyzed
cell movement by wound healing (scratch) assay.
Representative data of the wound healing tests on both
cell lines shown in Fig. 1d are statistically summarized in
Fig. 1c. Similarly to the results of the single-cell tracking
assay, drug-treated DK-MG cells closed the wounded
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Fig. 1 Impact of Akt and/or PI3K/mTOR inhibition on the migratory behavior of DK-MG and SNB19 cells assessed via single-cell tracking (a, b) and
wound healing (c, d) tests. Part A illustrates migration paths of 20–30 representative cells during 5 h, for each treatment. For each cell, its initial
position was set to the origin of coordinate system. Black circles denote the final cell locations at time = 5 h. The corresponding time lapse videos
are given in Additional file 3: movie S1. Part b summarizes the mean (± SE) migration speed values (i.e. total distance, TD divided by time) from
at least 400 cells per treatment. The bar graphs in C depict the impact of inhibitor treatment on the wound closure rate in DK-MG and SNB19
cell monolayers, expressed in unit area per min [μm2/min]. Each bar represents the mean ± SE of at least three independent experiments, each
performed four times. Phase contrast images of GBM cells shown in part d were acquired at 0 and 6 h after the wound was made. White color in
the right-side column of d represents the cell-devoid area, black and grey colors show areas covered with cells at time = 0 and 6 h, respectively.
“*” stands for p < 0.05. “n.s.” means “not significant”
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area much slower (by ~ 65–70%) than control cell sam-
ples (Fig. 1c, d).
A further interesting finding of the wound healing test
was that the Akt-inhibitor was less effective in SNB19
cells (Fig. 1c, d). Thus, treatment with MK-2206 alone
only moderately (~ 20%) affected the wound closure rate
of SNB19 cells. Besides this, compared to drug-free con-
trols, treatment of SNB19 cells with PI-103 alone and
with both drugs caused, respectively, an ~ 35 and ~ 45%
decrease in the wound healing rate compared with the
control cells (Fig. 1c), which is much less than the
almost 70% inhibition observed in drug-treated DK-MG
cells. Qualitatively similar data were obtained on irra-
diated cells (data not shown).
Effect of MK-2206 alone and in combination with PI-103
on colony-forming ability after irradiation
We further analyzed whether the Akt inhibition alone
or in combination affected the radiation sensitivity of
tumor cells. Figure 2 shows the normalized colony-
forming curves of untreated and drug-treated cells
plotted against the radiation dose, along with the best
fit curves of the LQ model (Eq. 1) to the survival
data. The plating efficiencies (PE) of control cell
Fig. 2 Colony-forming ability of irradiated DK-MG (a) and SNB19 (b) cells pre-treated for 3 h prior to IR with MK-2206, PI-103 or both.
Cells were seeded for the colony-forming test 24 h after IR. Ten to twelve days later, colonies containing at least 50 cells were counted
as survivors. Data derived from at least five independent experiments for each cell line (each performed four times) were pooled
together and fitted to a linear-quadratic equation (Eq. 1). The SE values are indicated by error bars. “*” means p < 0.05. “n.s.” means
“not significant”
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samples, as well as the values obtained with the LQ
model, including the colony-forming fraction at 2 Gy
(CF2), the radiation exposure dose required to reduce
colony-forming ability by 10% (D10) and the growth inhib-
ition factor (IF10) are summarized in Additional file 2:
Table S3.
As seen in Fig. 2 and in accordance with our pre-
vious results [24], PI-103 alone acts as a potent radio-
sensitizer in both cell lines (Fig. 2, curves 2 in parts
A and B). In contrast, MK-2206 given alone had little - if
any - effect on the radiation sensitivity of DK-MG cells
(curve 3, Fig. 2a) and, unexpectedly, it significantly
increased the radiation resistance of SNB19 cells
(curve 3, Fig. 2b). Upon combined drug treatment,
MK-2206 only slightly enhanced the radiosensitizing
effect of PI-103 in DK-MG cells (Fig. 2a, curve 4),
without affecting the PI-103-mediated radiosensitiza-
tion in SNB19 cells (Fig. 2b, curve 4).
Effects of MK-2206, PI-103 and/or irradiation on cell cycle
To find the molecular basis and to identify the mecha-
nisms underlying the absence of the radiosensitizing effect
of the Akt inhibitor MK-2206 in DK-MG cells (Fig. 2a) or
the radioresistance in respective SNB19 cells (Fig. 2b) the
attempts were focused on the inhibitor’s possible impact
on cell cycle progression. The data for both cell lines are
summarized in Fig. 3. The large fractions of cells in the S-
and G2/M-phases (> 70%) in control non-irradiated probes
(Fig. 3) show that the cells were growing exponentially at
the start of experiments. As expected, 30min post-IR,
non-irradiated and irradiated cells (within the respective
cell line) exhibited similar cell cycle phase distribution
Fig. 3 Cell cycle-phase distribution in DK-MG (a) and SNB19 (b) tumor cells treated for 3 h with PI-103, MK-2206 either alone or in combination
and irradiated with 8 Gy. Thirty minutes and 24 h after IR cells were fixed, permeabilized, stained with propidium iodide, and analyzed for DNA
content by flow cytometry. Data are presented as means (± SE) of at least three independent experiments
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(Fig. 3). However, as shown previously [24], prolonged
incubation with PI-103 caused an increase of G1 phase
cells from about 40% to ~ 60%. In contrast, upon a long-
term incubation with MK-2206, the cell cycle phase
distributions in both cell lines were nearly the same as in
respective non-treated controls (Fig. 3). Combined pro-
longed drug treatment caused a strong G2/M arrest in
irradiated samples of both cell lines similar to that
observed after treatment with PI-103 alone and IR.
The cell cycle impairment caused by PI-103 alone and
in combination shown above (Fig. 3) led us to determine
the expression levels of several cell-cycle regulating
factors such as cyclin dependent kinases (Cdk1, Cdk4),
and pRb by Western blotting. As shown in the
Additional file 4: Figure S1, the expressions of Cdk1 and
pRb decreased although to a different extent in both GBM
lines after prolonged exposure to PI-103 alone or in com-
bination, especially in non-irradiated cells. In contrast, the
levels of cell cycle-related proteins were mostly unchanged
in non-irradiated cells treated with MK-2206 alone.
To sum up, long-term incubation with PI-103 caused
a significant G1 arrest in both cell lines, but combined
with IR it produced a strong G2/M arrest. In contrast,
treatment with MK-2206 alone had no influence on the
cell cycle. In both cell lines, combined treatment with
both drugs and IR caused a profound G2/M arrest 24 h
post-IR, similar to that induced by PI-103 alone and IR.
Effects of MK-2206 and PI-103 and/or radiation on late-
stage apoptosis and autophagy
To further dissect the mechanisms underlying the radi-
ation survival of GBM cells after single Akt- and com-
bined PI3K/Akt/mTOR-inhibition illustrated in Fig. 2, we
also analyzed cleaved PARP, a well-known marker of
apoptosis. As seen in Additional file 4: Figure S2, DK-MG
cells treated with PI-103 alone or in combination with
MK-2206 exhibited negligible levels of cleaved PARP, in-
dependent of IR, whereas no any cleaved PARP was
detected in SNB19 samples. Likewise, the Akt-inhibitor
did not induce any measurable amounts of cleaved PARP.
In addition, the apoptosis rate was evaluated by the
sub-G1 fraction. As seen in Fig. 4, inhibitor-treated and
irradiated DK-MG samples contained much larger frac-
tions of apoptotic cells and debris than corresponding
SNB19 cell samples, especially 24 h after IR.
Because the Akt/mTOR pathway is recognized as a
major pathway regulating autophagy [16], we also stud-
ied the role of autophagy in the development of radi-
ation resistance in MK-2206-treated cells, especially in
case of the SNB19 cell line. To this end, we detected the
autophagosomal membrane-bound LC3B protein along
with the expression of the p62/sequestome protein, a
pleiotropic protein that is consumed during autophagy
[31]. As seen in the Additional file 4: Figure S3, IR
increased the expression of LC3B-I and LC3B-II proteins
in both cell lines. This result is corroborated by earlier
findings that radiation enhances autophagy in tumor
cells (for review, see [32]). We also found that the dual
PI3K- and mTOR-inhibitor PI-103 alone and especially
in combination with MK-2206 strongly induced autoph-
agy, as evident from the increased levels of LC3B-II
protein (Additional file 4: Figure S3). However, the ra-
tio between LC3B-II and LC3B-I was lower in irradi-
ated cells compared to non-irradiated. Furthermore,
the enhanced autophagy in drug-treated samples, de-
tected by LC3B-II expression, was also corroborated
by the strong depletion of p62 protein, another
marker of autophagy (Additional file 4: Figure S3).
These findings agree well with the results of Fan et
al. (2017) who found that dual inhibition of PI3K and
mTOR promotes survival of glioma cells by inducing
cytoprotective autophagy [33]. Regarding MK-2206,
the extent of drug-induced autophagy measured by
LC3B-II expression was lower than that induced by
PI-103. Likewise, when assessed by p62 expression,
MK-2206 alone induced autophagy to a much lesser
extent than PI-103. The highest extent of autophagy
was observed in samples treated with both inhibitors
simultaneously. Interestingly, the background expres-
sion of p62 in DK-MG cell line was much lower than
in SNB19 cells. The difference may reside in the wild
type status of p53 in DK-MG cells because functional
p53 is known to inhibit autophagy [34].
Effects of MK-2206 and PI-103 and/or radiation on the
expression of marker proteins
To further investigated the molecular basis for the ob-
served effects in MK-2206-treated tumor cells with or
without addition of PI-103, or IR exposure (Figs. 1, 2),
we studied the expression of two groups of proteins.
The first group (Fig. 5 and Additional file 4: Figure S4)
includes several marker proteins of the PI3K-pathway,
i.e. p-Akt and mTOR, along with p-4E-BP1 and p-S6.
The second group includes two proteins of the
MAPK-pathway, i.e. MEK1/2 and Erk1/2 (Additional file
4: Figure S5). Figure 5 shows exemplarily Western blot
data of control and drug-treated cells probed for p-Akt,
p-mTOR, p-S6 and p-4E-BP1 proteins 30 min and 24 h
after IR with 8 Gy. Samples shown on the left- and
right-hand sides (LHS, RHS) of Fig. 5 were obtained
from DK-MG and SNB19 cells, respectively.
Complete loss of PTEN in PTEN-mutated SNB19
cells, commonly leads to an over-activation of the PI3K
pathway. As seen in Fig. 5 (RHS column), the expres-
sion of p-Akt in SNB19 cells was much higher than in
DK-MG cells containing wild type PTEN. Addition of
MK-2206 or PI-103 either alone or in combination
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strongly reduced the p-Akt level after a 3-h drug treat-
ment, with and without IR. However, in accordance
with our previous findings [24], prolonged treatment
with PI-103 caused reactivation of the Akt function in
both cell lines. Thus, p-Akt expression (1.1 a.u.) in
SNB19 cells almost recovered to the background level
of 1.4 a.u. (Fig. 5, RHS). In contrast, both cell lines
remained depleted of p-Akt after prolonged treatment
with MK-2206 alone or in combination with PI-103, inde-
pendent of IR exposure.
In addition to p-Akt, we analyzed the expression of
p-mTOR and its downstreams, ribosomal S6 and trans-
lational repressor 4E-BP1 proteins, which are known to
influence cell-cycle progression and cell growth [35, 36].
The expression of p-mTOR decreased after short in-
cubation with PI-103 alone or in combination with
MK-2206 (Fig. 5) in both cell lines. Upon long-term
exposure to both drugs, p-mTOR expression almost
returned to the control level in SNB19 cells, but not in
DK-MG cells. As a result of mTOR inhibition by PI-103,
both p-4E-BP1 and p-S6 were also strongly suppressed
30min or even depleted (p-S6) 24 h post-IR (Fig. 5) in
cells treated with PI-103 alone and especially in combi-
nation with MK-2206.
Contrary to the inhibition of p-mTOR by PI-103,
MK-2206 moderately increased the p-mTOR level in
SNB19 cells (but not in DK-MG cells) 30 min post-IR
(1.0–1.1 a.u.), as compared to control (0.84–0.89 a.u.)
Fig. 4 Flow-cytometric analyses of the sub-G1 DNA content distribution in DK-MG and SNB19 cells subjected to drug-IR treatments were
performed 30 min or 24 h after IR. The cells were detached with trypsin, treated with saponin and RNAse, stained with propidium iodide and
then analyzed for red fluorescence by flow cytometry. The samples include both floating and trypsinized cells. Changes in the sub-G1 fraction are
depicted as folds of increase (means ± SE), normalized to respective non-irradiated drug-free controls (30 min post-IR). The sub-G1 fraction
includes hypodiploid nuclei and debris, computed from the flow cytograms with the Flowing Software for n = 3 independent experiments
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and especially to PI-103-treated cells (0.69–0.71 a.u.;
Fig. 5). As a result, p-4E-BP1 and p-S6 proteins were also
increased after addition of MK-2206 alone to SNB19 cells,
whereas they were strongly reduced or even vanished after
prolonged PI-103 treatment. At the same time, in DK-MG
cells the expressions of p-mTOR and p-4E-BP1 remained
mostly unchanged (30min and 24 h post-IR) in the
samples treated with MK-2206 alone or in combination
with PI-103. The corresponding bands of β-actin are
shown in Additional file 4: Figure S4.
Because of the mutual dependence of the PI3K and
MAPK pathways [37], we also analyzed two kinases of
the MAPK signaling pathway, p-MEK1/2 and p-Erk1/2
(Additional file 4: Figure S5). The MAPK pathway,
which is frequently mutated in cancer cells [38, 39],
transmits signals from surface receptors to stimulate cell
Fig. 5 Expression patterns of various marker proteins of PI3K-pathway in DK-MG and SNB19 cells treated with DMSO (control) or the indicated
compounds for 3 h before IR with 8 Gy and detected 30 min and 24 h thereafter. Each protein band was normalized to the intensity of β-actin
used as loading control. The protein/β-actin ratios are indicated by the numbers. The Western blot experiments were repeated independently at
least three times
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survival, proliferation and migration [40]. We found that
a short incubation with MK-2206 alone or in combi-
nation with PI-103 slightly increased the expressions of
p-MEK1/2 and p-Erk1/2 (Additional file 4: Figure S5).
However, after prolonged incubation with MK-2206
alone or in combination with PI-103 the effect was
less evident.
Next we studied Rheb protein, which was shown to acti-
vate mTORC1 in vitro [41]. As seen in Additional file 4:
Figure S6, after a short incubation with MK-2206 the
Rheb expression was increased in SNB19 but not in
DK-MG cells. At 24 h post-IR the expression of Rheb was
higher in all drug-treated and irradiated probes of SNB19
cells compared to non-treated controls. At the same time,
the expression of Rheb in DK-MG cells remained mostly
unchanged by drug application.
Effects of MK-2206 and PI-103 and/or radiation on DNA
damage
To elucidate the cause for the radioprotective effect of
the Akt inhibitor MK-2206 in colony-forming tests, es-
pecially in SNB19 cells (Fig. 2), we evaluated DNA dam-
age in control and drug-treated cells after IR. The
results are statistically summarized in Fig. 6 as the mean
(± SE) values of the amount of DNA damage detected
30min and 24 h after IR in all cell probes. As seen in
Fig. 6a, irradiated drug-free DK-MG cells showed in-
creased residual damage 24 h post-IR. However, no dif-
ferences in the induction and repair of DNA damage
were found between irradiated DK-MG cells independ-
ent of drug pretreatment. On the contrary, in irradiated
SNB19 cells (Fig. 6b) the residual (24 h post-IR) damage
to DNA after addition of PI-103 alone or in combination
Fig. 6 DNA damage in control and drug-treated and/or irradiated DK-MG (a) and SNB19 (b) cells assessed by histone γH2AX 30min and 24 h
post-IR with 8 Gy and quantified by flow cytometry. The bar graphs are the means (± SE) of at least 3 independent experiments. The data of each
cell line are normalized to the initial γH2AX content (at 30 min post-IR) detected in drug-free non-irradiated controls. “a.u.” means arbitrary units,
“*” means p < 0.05
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with MK-2206 was much higher than in drug-free irra-
diated cells. Interestingly, MK-2206 alone did not in-
fluence the degree of induced or residual DNA damage
in both cell lines.
Driven by the finding that both inhibitors added alone
differently affect the repair of DNA damage in irradiated
SNB19 cells (Fig. 6b), without influencing the repair
process in DK-MG cells (Fig. 6a), we analyzed the
expression of several DNA repair proteins. Figure 7
shows representative Western blot detections of several
DNA repair proteins in both cell lines treated with drugs
and IR. Thirty minutes after IR, the expression levels of
DNA-PK, ATM and ATR proteins were very similar in
control and drug-treated samples of DK-MG cells (Fig. 7,
LHS). However, 24 h post-IR the expression of DNA-PK
and ATM proteins was higher in drug-treated than in
Fig. 7 Representative Western blots of several DNA repair proteins in two tumor cell lines subjected to 3-h pretreatment with both tested drugs
before IR. Cell lysates were prepared 30 min and 24 h after irradiation with 8 Gy. For details, see legend to Fig. 5
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drug-free DK-MG cell samples. On the contrary, drug
treatment did not cause any changes in the expression
of DNA-PK and ATM in SNB19 cells (Fig. 7, RHS). The
expression of ATR was mostly unchanged throughout
the experiment in both cell lines, except within irra-
diated SNB19 cells treated for more than 24 h with
PI-103 alone or in a combination.
Furthermore, we studied the expression of DNA repair
proteins Rad50, Rad51, Ku70 and Ku80 (Additional file 4:
Figure S7). We found no differences in the expression of
Rad50, Ku70 and Ku80 in both cell lines throughout the
whole study. In contrast, the expression of Rad51 was
strongly reduced in non-irradiated samples of both cell
lines treated with PI-103 alone or in combination with
MK-2206 (Additional file 4: Figure S7). Given that Rad51
operates mostly in the G2 phase of the cell cycle [42], the
decrease in Rad51 can be explained by the G1-arrest after
addition of PI-103. However, despite the strong reduction
of Rad51 in both cell lines, DK-MG cells showed normal
repair of DNA damage, whereas SNB19 cells showed pro-
tracted DNA repair. This means that the impaired DNA
repair capacity revealed by the high residual histone
γ-H2AX levels in SNB19 cells treated with PI-103 alone
or in combination with MK-2206 (Fig. 6b) cannot be
explained by the reduction of Rad51 (Additional file 4:
Figure S7, RHS). The corresponding blots for β-actin
expression are shown in Additional file 4: Figure S8.
Effects of MK-2206 and PI-103 on the plasma membrane
properties probed by electrorotation (ROT)
In a series of studies, we have shown recently that the
two glioblastoma cell lines (DK-MG and SNB19) studied
here are very different not only in their invasiveness and
migratory behavior [25, 43], but also in their morpho-
logical appearance including membrane surface area and
folding [44], analyzed by electron microscopy and elec-
trorotation. Although derived from the same tumor en-
tity, the two cell lines differ markedly in the mutational
status of the most prominent tumor suppressors PTEN
and p53 [43, 44]. Both genes are wild type in DK-MG
cells, whereas in the SNB19 cell line both genes are mu-
tated, which leads to a marked difference between the
two cell lines regarding their phospholipid and mem-
brane synthesis (for detail, see Fig. 7 in [44]). Further-
more, the two cell lines differ greatly from each other in
their response to the pharmacological inhibition of PI3K
and mTOR in terms of migration [25]. Taken together,
the above mentioned findings prompted us to analyze in
this study the effects of the PI3K-Akt-mTOR inhibition
not only on GBM cell migration but also on the plasma
membrane morphology, which is closely related to cellu-
lar motility and invasion [43].
As shown above (Fig. 5), a 3-h incubation with MK-2206
had different effects on the mTOR expression in tested
cell lines, i.e. an up-regulation in SNB19 cells and a
down-regulation in DK-MG cells. In view of the essen-
tial role of mTOR in cellular metabolism, including
protein and phospholipid synthesis [45], it can be
expected that the plasma membrane properties will be
differently affected by MK-2206 in the two tested GBM
cell lines. To prove this assumption, we examined the
impact of MK-2206 and PI-103 on the plasma mem-
brane folding and area by means of the contra-rotating
field (CRF) technique [30]. Using this technique, we
measured the area-specific plasma membrane capaci-
tance Cm [μF/cm
2] and the whole-cell capacitance CC
[pF]. Cm reflects the morphological complexity of the
cell surface, such as membrane folds, protrusions and
microvilli [44], whereas the parameter CC accounts for
the total electrically accessible cell membrane, inclu-
ding both smooth and folded membrane regions. The
results of electrorotation experiments are shown in the
Additional file 4: Figures S9, S10 and summarized in
Additional file 2: Table S4.
As seen in Additional file 2: Table S4, the Cm value of
control DK-MG cells (~ 2.5 μF/cm2) is much lower than
that of SNB19 cells (~ 3.9 μF/cm2), which can be explained
by a lower degree of membrane folding in DK-MG cells
[44]. Treatment with the Akt inhibitor MK-2206 for 3 h
significantly reduced both Cm and CC of DK-MG cells by
~ 25% (2.5→ 1.86 μF/cm2) and ~ 33% (19.5→ 13.2 pF),
respectively, indicating a marked decline of the plasma
membrane area. In contrast and as expected, in SNB19
cells, MK-2206 reduced the Cm and CC by ~ 15% (3.9→
3.3 μF/cm2) and 25% (30.3→ 23.0 pF), respectively, to a
lesser extent than in DK-MG cells.
Interestingly, PI-103 also reduced both Cm and CC of
DK-MG, but not as strong as MK-2206. Combined
MK-2206 and PI-103 treatment caused the strongest
observed reduction of Cm (− 30%) and CC (− 40%) in
DK-MG cells compared to controls, while no additional
reduction of Cm was observed in SNB19 cells treated with
both drugs. In the light of the recent finding that the
plasma membrane turnover actively contributes to cell
migration [46], the drug-induced reduction of the
membrane surface area (probed by CC) in both cell lines
(Additional file 2: Table S4), may at least partly be res-
ponsible for the observed drug-mediated inhibition of cell
migration revealed by wound-healing assay (Fig. 1c, d).
Discussion
Protein kinase B or Akt is the primary downstream
mediator of PI3K signaling. It influences numerous cellular
processes, including survival, growth, proliferation, angio-
genesis, metabolism and migration [47]. The Akt family of
kinases includes three members, Akt1, Akt2 and Akt3.
Several studies have investigated the specific roles of indi-
vidual Akt family members in cell migration and invasion
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[48, 49]. Interestingly, Akt1 has been found to function as
an inhibitor of migration and invasion in breast [48] and
ovarian [49] cancer cells, whereas inhibition of Akt2 has
no effect on cell motility [48].
In the present study, we tested the effect of targeting
Akt using the pan-Akt inhibitor MK-2206, which
inhibits all three isoforms of Akt, with the intention of
impeding the migration and radiation resistance of two
GBM cell lines differing in p53 and PTEN status [44],
and therefore exhibiting different background expression
of PI3K pathway proteins, including Akt. In addition, we
examined whether MK-2206 can enhance the radiosen-
sitizing effect of the dual PI3K/mTOR inhibitor PI-103.
We found that MK-2206 strongly inhibited the expres-
sion of p-Akt in both cell lines (Fig. 5). However, con-
trary to expectations and despite depletion of p-Akt,
MK-2206 did not radiosensitize both tumor cell lines
but instead increased the radiation resistance of SNB19
cells (Fig. 2b, curve 3). Moreover, MK-2206 only moder-
ately impeded SNB19 cell motility, but strongly affected
the migration of DK-MG cells (Fig. 1). These results
may be due to the following reasons: (i) MK-2206 did
not induce cell cycle arrest (Fig. 3); (ii) neither did it in-
duce excessive autophagy or apoptosis (Additional file 4:
Figures S2, S3, Fig. 4); (iii) MK-2206 caused an aberrant
activation of mTOR and its downstreams in SNB19 cells
(Fig. 5); (iv) MK-2206 had no effect on the extent of
induced and residual DNA damage in irradiated cells
(Fig. 6). Furthermore, it did not enhance the radiosen-
sitizing effect of PI-103 (Fig. 2).
The lack of a radiosensitizing effect of MK-2206 on
GBM cell lines found in our study differs from the find-
ings of Chautard et al. (2010) who showed a moderate
increase of radiation sensitivity of two glioma cell lines
treated with the Akt inhibitor IV (B2311) [21]. Likewise,
our findings are different from those of Li et al. (2009)
and Holler et al. (2016) who showed, respectively, an in-
creased cell killing in colony-forming test of U87-MG
and H460 cells treated with MK-2206 [20, 22]. These
discrepancies might reside either in the particular Akt
inhibitor, treatment protocol or the cell line used. In-
deed, a differential response of tumor cells to full inhib-
ition of Akt was observed and discussed elsewhere [22,
50]. For instance, in the study of Holler et al. (2016) in
Fig. 8 Schematic outline of possible signaling pathways responsible for different radiation responses of SNB19 cells pre-treated either by MK-2206
(a) or PI-103 (b). Despite strong depletion of p-Akt in MK-2206-treated cells, there was a moderate increase of its downstream p-mTOR (a). In
contrast, p-mTOR was decreased in PI-103-treated cells (b) and consequently, its downstream effectors p-4E-BP1 and p-S6 were decreased as well
(b). In sharp contrast, in MK-2206-treated cells the levels of p-4E-BP1 and p-S6 remain almost the same as in non-treated cells (A). In addition,
inhibiting Akt by MK-2206 moderately stimulates the activity of MEK1/2 and Erk1/2 (A) whereas the effect was not seen after treatment with
PI-103 (b). The proposed pathways are derived from the findings shown in Figs. 1, 2, 3, 4, 5, 6, 7 and Additional file 4: Figsure S1-S9, and also
from previously published data [37]. Non-detected proteins are marked with dashed lines. Increased and decreased protein expression levels
compared to corresponding control cells, are denoted by the symbols ↑ and ↓, respectively, as detected by Western blot analysis. (For details,
see the Discussion section)
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addition to a H460 cell line responsive to Akt inhibitor,
there was a non-responsive A549 cell line which did not
show any increased radiation sensitivity after Akt
targeting [22].
Based on our findings we suggest a simplified scheme
presented in Fig. 8. Parts A and B of Fig. 8 illustrate the ef-
fects of MK-2206 (A) and PI-103 (B) on the radiation sen-
sitivity of SNB19 cells. One of the possible reasons for the
inability of MK-2206 to increase the radiation sensitivity
of both cell lines, or in case of SNB19 cells to cause radio-
resistance, might be the activation of negative feedback
loops leading to unimpeded or even increased mTOR
function in MK-2206-treated cells (Fig. 5, line: 8 Gy, 30
min). As is known, Akt phosphorylates and thereby in-
hibits the heterodimer TSC1/TSC2, which in turn inhibits
activation of the small GTPase Rheb, thus promoting
mTORC1 activation [41]. Therefore, mTORC1 cannot be
activated in drug-treated cells lacking p-Akt. As evident
from Fig. 5, the expression of p-Akt was similarly depleted
in cell samples treated shortly with either MK-2206 or
PI-103. However, the expression of its downstream, i.e.
mTOR was decreased only in PI-103-treated but not in
MK-2206-treated SNB19 cells. Moreover, in MK-2206-
treated SNB19 cells the expression of p-mTOR was even
increased compared to PI-103-treated cells. The latter
finding can be explained by the moderately increased
expression of Rheb in SNB19 cells treated with MK-2206
(Additional file 4: Figure S6). Apparently, the activation of
mTOR measured 30min post-IR resulted in increased
protein synthesis and subsequently enhanced colony-
forming ability by (a) phosphorylating and inactivating
the translational inhibitor 4E-BP1 and (b) by phosphoryl-
ating and activating S6 kinase in MK-2206-treated SNB19
cells. This in turn likely enhanced the radioresistance of
SNB19 cells treated with the Akt inhibitor MK-2206. The
same explanation applies to the moderate effect of
MK-2206 on the migration of SNB19 cells reported here.
Another reason for the differential effect of MK-2206 on
the migration of DK-MG and SNB19 cells might be a
different ratio of three Akt isoforms in these cell lines,
which were not studied here separately. Subsequently, this
may suggest the existence of isoform-specific effects on
the molecular cascades that lead to the rearrangement of
actin cytoskeleton, lamellipodium extension, and cell
spreading, and MMPs (matrix-metalloproteinase) produc-
tion [51]. Future works in this direction on an extended
cell sample should bring more clarity in this matter.
Besides inhibition by Akt, the TSC1/2 complex, a
negative regulator of mTORC1, can also be inhibited by
the MAPK pathway [52]. Phosphorylation of TSC2 by
Erk promotes dissociation of the tuberous sclerosis
complex and attenuates TSC2-mediated inhibition of
mTOR in cells. Therefore, a compensatory activation of
the MAPK pathway (Additional file 4: Figure S5) in
response to individual (here MK-2206) inhibitors [53] of
the PI3K pathway can be another plausible explanation
for the increased radiation resistance of SNB19 cells
treated with the Akt inhibitor (Fig. 2b). It is known that
both the PI3K and the MAPK pathway include critical
factors for enhanced proliferation and survival of tumor
cells [37] and constitutive activation of both pathways is
correlated with a limited response to radiotherapy.
These linear cascades rarely act as independent parallel
pathways; rather they influence each other at different
points and phases of signal propagation [54]. Because
the MAPK pathway is responsible for cell survival and
proliferation, we hypothesize that feedback activation of
MEK/Erk proteins counteracts the cell cytotoxicity of
Akt inhibition. Indeed, 30 min post-IR we observed an
increase of p-MEK and p-Erk1/2 expressions, at least
moderately, in MK-2206-treated samples (Additional file
4: Figure S5), which reflects the MAPK pathway acti-
vation following an Akt inhibition. An activation of
Erk1/2 lead to the activation of Rheb and subsequently
to the activation of mTORC1. Another reason for the
inability of MK-2206 to increase the radiation sensitivity
of both cell lines might be an activation of cytoprotective
autophagy. As shown previously by Fan et al. (2010),
PI-103 induces autophagy as a survival pathway in
glioma cells [33]. Indeed, as seen in Additional file 4:
Figure S3, PI-103, either alone or in combination with
MK-2206, induced autophagy measured by the induction
of LC3B-II or depletion of p62 proteins. However, the
extent of (cytoprotective) autophagy induced by PI-103
was much higher compared to that induced by MK-2206
alone, especially in SNB19 cells. Thus, cytoprotective
autophagy induced by MK-2206 alone can be ruled out
as a reason for the increased radiation resistance of
MK-2206-treated cells.
Further we found no differences in the induction and
repair of DNA damage (Fig. 6) and the expression of DNA
repair proteins (Fig. 7 and Additional file 4: Figure S7)
between non-treated samples and those treated with
MK-2206, with the exception of increased residual DNA
damage in PI-103-treated SNB19 cells. The effect of
PI-103 is corroborated by our previously published data
[24]. Therefore, the enhanced survival of irradiated cells
treated with MK-2206 can be explained by the absence of
increased DNA damage and sufficient DNA repair. In
addition, MK-2206 did not cause any cell cycle arrest in
both cell lines (Fig. 3) thus allowing the cells unhampered
proliferation and survival after IR.
Conclusions
Our study provides a proof-of-concept that inhibition of
Akt by MK-2206 might be a promising therapeutic strategy
for increasing radiation sensitivity of tumor cells. However,
the aberrant activation of mTOR in response to Akt
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inhibition in PTEN mutated cell lines, may counteract or
even prevent, radiosensitization. Therefore, the therapeutic
window needs to be carefully defined, or a combination of
Akt and mTORC1 inhibitors should be considered.
Additional files
Additional file 1: Supplemental Materials. The primary and secondary
antibodies used in this paper. (DOCX 57 kb)
Additional file 2: Table S1. Cell cycle-phase distribution in control and
irradiated (2 or 8 Gy) SNB19 tumor cells. The cells were fixed either 30
min or 24 h after IR, permeabilized, stained with propidium iodide, and
analyzed for their DNA content by flow cytometry. Data are presented as
means (± SD) from at least three independent experiments. For detailed
description, see legend to Fig. 3. Table S2. Detection of γH2AX as a
measure of DNA damage in SNB19 cells by flow cytometry. Mean γH2AX
values are normalized to the non-irradiated control (30 min post-
irradiation). The data are means ±SE from at least three independent
experiments. Table S3. Cloning efficiencies and radiosensitivity
parametersa of in vitro irradiated tumor cell lines untreated and
pretreated with the MK-2206 and PI-103 either alone or in combination.
aMean (± SE) from at least three independent experiments; bCF2 is the
colony-forming ability at 2 Gy; cD10 is the radiation dose required to
reduce colony-forming ability by 10%; dThe growth inhibition factor IF10
was calculated as (D10 control)/(D10 + inh.). Table S4. Impact of MK-2206,
PI-103 either alone or in combination on the area-specific plasma
membrane capacitance Cm, the whole-cell capacitance CC
* and cell
radius. *The data derived from the ROT experiments shown in the
Additional file 4: Figure S10 represent the means ± SE of at least 60 cells.
(DOCX 63 kb)
Additional file 3: Movie S1. Cell trajectory analysis of control and drug-
treated DK-MG and SNB19 tumor cells. Cells were imaged every 10 min
by time-lapse microscopy using a Nikon BioStation IM-Q (Nikon, Melville,
NY). For single-cell tracking experiments, about 104 cells in 2 ml CGM
were plated into a Petri dish (diameter 35 mm) and cultivated overnight.
In each experiment, time-lapse images were acquired over a 23-h period,
using a × 10 phase contrast objective. The initial position of each cell was
set to the origin (0,0). Trajectories of control cells of both cell lines are
shown on the left and MK-2206-treated cells on the right side,
respectively for a 5 h timeframe. MK-2206-treated cells were pretreated
for 3 h with the drug before recording. The movies are played back at a
rate of 10 frames per second (sped up 6000× real time). (AVI 5121 kb)
Additional file 4: Figure S1. Western blot analysis of cell-cycle regula-
tory protein expression in drug-treated DK-MG and SNB19 cells, normal-
ized to β-actin intensity (loading control). Numbers denote protein/β-
actin ratios (details in Fig. 5 legend). Figure S2. Western blot analysis of
PARP- and cleaved PARP-expression in drug-treated DK-MG and SNB19
cells. Numbers denote protein/β-actin ratios. Figure S3. Western blot
analysis of autophagy marker proteins LC3B and p62 in drug-treated DK-
MG and SNB19 cells. Numbers denote protein/β-actin ratios (details in
Fig. 5 legend). Figure S4. Western blot analysis of β-actin expression for
proteins shown in Fig. 5 and Fig.7 (details in Figs. 5 and 7 legends).
Figure S5. Western blot analysis of p-MEK1/2 and p-Erk1/2 in drug-
treated DK-MG and SNB19 cells. Numbers denote protein/β-actin ratios
(details in Fig. 5). Figure S6. Western blot analysis of Rheb in drug-
treated DK-MG and SNB19 cells. Numbers denote protein/β-actin ratios
(details in Fig. 5 legend). Figure S7. Western blot analysis of DNA-repair
proteins in drug-treated DK-MG and SNB19 cells. Numbers denote pro-
tein/β-actin ratios (details in Fig. 5 legend). Figure S8. Western blot ana-
lysis of β-actin expression for proteins depicted in Fig. S7 (details in Fig. 7
legend). Figure S9. Cumulative plots of radius-normalized fc values (fc·a)
vs. external conductivity of DK-MG (A) and SNB19 (B) cells were obtained
by contra-rotating-field (CRF) technique. Symbols represent mean fc·a (±
SD) values from 20 cells measured at ~ 10, 25 and 40 μS/cm. Lines are
best fits of Eq. 2 to the data. The steeper line slopes for DK-MG cells (A)
imply smaller Cm values compared to SNB19 cells (B). For Cm and CC
values, calculated with Eq. 3, see Additional file 2: Table S4. Figure S10.
Impact of drug-treatment on cell radius, Cm, and CC values of DK-MG (A)
and SNB19 (B) cells. “*” denotes significant difference at p < 0.05. “n.s.”
means “not significant”. (DOCX 753 kb)
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